Flutamide/NN
in/IN
the/DT
treatment/NN
of/IN
hirsutism/NN
:/:
long-term/JJ
clinical/JJ
effects/NNS
,/,
endocrine/JJ
changes/NNS
,/,
and/CC
androgen/NN
receptor/NN
behavior/NN
./.

OBJECTIVE/NN
:/:
To/TO
investigate/VB
the/DT
long-term/JJ
effects/NNS
of/IN
treatment/NN
with/IN
low/JJ
doses/NNS
of/IN
flutamide/NN
on/IN
clinical/JJ
and/CC
hormonal/JJ
parameters/NNS
,/,
as/RB
well/RB
as/IN
on/IN
the/DT
androgen/NN
receptor/NN
status/NN
,/,
in/IN
hirsute/JJ
women/NNS
./.
=====
DESIGN/NN
:/:
Eighteen/CD
hirsute/JJ
patients/NNS
with/IN
regular/JJ
menses/NNS
were/VBD
studied/VBN
basally/RB
and/CC
during/IN
treatment/NN
with/IN
125/CD
mg/NN
flutamide/NN
,/,
three/CD
times/NNS
per/IN
day/NN
for/IN
12/CD
months/NNS
./.
=====
Barrier/NN
or/CC
intrauterine/JJ
contraception/NN
was/VBD
used/VBN
during/IN
the/DT
study/NN
in/IN
sexually/RB
active/JJ
women/NNS
./.
=====
Safety/NN
parameters/NNS
were/VBD
assessed/VBN
throughout/IN
the/DT
study/NN
./.
=====
Hirsutism/NN
,/,
graded/VBN
by/IN
the/DT
modified/VBN
Ferriman-Gallwey/JJ
score/NN
,/,
and/CC
hormonal/JJ
parameters/NNS
were/VBD
evaluated/VBN
basally/RB
and/CC
at/IN
4-month/JJ
intervals/NNS
during/IN
treatment/NN
./.
=====
Gonadotropin-releasing/JJ
hormone/NN
and/CC
ACTH/NN
stimulation/NN
tests/NNS
were/VBD
performed/VBN
before/IN
and/CC
after/IN
3/CD
to/TO
4/CD
months/NNS
of/IN
therapy/NN
./.
=====
In/IN
addition/NN
,/,
the/DT
concentration/NN
of/IN
androgen/NN
receptors/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
was/VBD
measured/VBN
,/,
in/IN
both/CC
the/DT
follicular/JJ
and/CC
luteal/JJ
phases/NNS
of/IN
the/DT
menstrual/JJ
cycle/NN
,/,
basally/RB
and/CC
after/IN
4/CD
months/NNS
of/IN
flutamide/NN
treatment/NN
./.
=====
RESULTS/NNS
:/:
Flutamide/NN
was/VBD
well/RB
tolerated/VBN
in/IN
all/DT
women/NNS
,/,
with/IN
the/DT
noticeable/JJ
exception/NN
of/IN
one/CD
patient/NN
who/WP
presented/VBD
increased/VBN
serum/NN
transaminase/NN
after/IN
8/CD
months/NNS
of/IN
therapy/NN
./.
=====
Hirsutism/NN
markedly/RB
improved/VBD
in/IN
all/DT
women/NNS
during/IN
the/DT
treatment/NN
(/(
Ferriman-Gallwey/JJ
score/NN
after/IN
1/CD
year/NN
:/:
4.1/CD
+/-/CC
0.5/CD
versus/CC
14.1/CD
+/-/CC
0.9/CD
)/)
./.
=====
A/DT
reduction/NN
of/IN
serum/NN
androgens/NNS
was/VBD
found/VBN
,/,
whereas/IN
no/DT
change/NN
was/VBD
observed/VBN
in/IN
either/CC
basal/JJ
or/CC
GnRH-stimulated/JJ
gonadotropins/NNS
or/CC
in/IN
the/DT
cortisol/NN
and/CC
17/CD
alpha-hydroxyprogesterone/NN
response/NN
to/TO
ACTH/NN
./.
=====
Cycles/NNS
remained/VBD
ovulatory/JJ
./.
=====
Before/IN
treatment/NN
,/,
the/DT
number/NN
of/IN
androgen/NN
receptors/NNS
was/VBD
higher/JJR
in/IN
the/DT
luteal/NN
than/IN
in/IN
the/DT
follicular/JJ
phase/NN
./.
=====
This/DT
rhythmic/JJ
differentiation/NN
disappeared/VBD
after/IN
the/DT
patients/NNS
had/VBD
been/VBN
given/VBN
the/DT
antiandrogen/JJ
drug/NN
./.
=====
CONCLUSIONS/NNS
:/:
Flutamide/NN
is/VBZ
effective/JJ
in/IN
the/DT
treatment/NN
of/IN
hirsutism/NN
but/CC
requires/VBZ
constant/JJ
surveillance/NN
of/IN
liver/NN
function/NN
./.
=====
Androgen/NN
receptor/NN
blockade/NN
might/MD
be/VB
potentiated/VBN
by/IN
a/DT
reduction/NN
of/IN
serum/NN
androgens/NNS
./.
=====
Flutamide/NN
affects/VBZ
androgen/NN
receptor/NN
behavior/NN
during/IN
the/DT
menstrual/JJ
cycle/NN
./.
=====
The/DT
meaning/NN
of/IN
this/DT
finding/NN
remains/VBZ
to/TO
be/VB
elucidated/VBN
./.